LP
XENE icon

Longaeva Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Longaeva Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,250
Closed -$363K – 417
2026
Q1 		$363K Buy
+6,250
New +$288K 0.01% 193

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Longaeva Partners's XENE Position: Q2 2026 in Review

Longaeva Partners sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 6,250 shares — an estimated $363K sold.

Longaeva Partners first reported a position in XENE in Q1 2026 and held it in 1 quarter. The position peaked at $363K in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Longaeva Partners reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Longaeva Partners sold 6,250 Xenon Pharmaceuticals shares in Q2 2026, an estimated $363K.
  • Longaeva Partners first reported a position in Xenon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Longaeva Partners's Xenon Pharmaceuticals position peaked at $363K in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.